Navigation Links
Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
Date:4/23/2008

tion, MT110 may be suited to treat established tumors as well as disseminated cancer cells, which frequently give rise to metastases."

About BiTE Antibodies

BiTE(R) antibodies are designed to direct the body's cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. BiTE antibodies have been shown to induce an immunological synapse between a T cell and a tumor cell in the same manner as observed during physiological T cell attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ultimately inducing a self-destruction process in the tumor cell referred to as apoptosis, or programmed cell death. In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations and at very low ratios of T cells to target cells. Through the process of killing cancer cells, T cells proliferate, which leads to an increased number of T cells at the site of attack.

Several antibodies in Micromet's product pipeline are BiTE antibodies and have been generated based on Micromet's proprietary BiTE antibody platform. The most advanced BiTE antibody is MT103 (MEDI-538), targeting CD19, and has provided proof-of-concept in an ongoing phase 1 clinical study in patients with advanced non-Hodgkin's lymphoma. MT110, which is targeting EpCAM (CD326) and is the first BiTE antibody with potential applications in the treatment of solid tumors, is in a phase 1 clinical trial in patients with lung and gastrointestinal cancers. Two additional BiTE antibodies, targeting CD33 and MCSP, are in preclinical development.

About Micromet, Inc. (http://www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and auto
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
2. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
3. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
4. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
5. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
6. Micromet Announces Changes in Management Team
7. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
8. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
9. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
10. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
11. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... TORONTO , May 22 2015 /CNW/ - The Taskforce ... are very appreciative of all the hard work that the ... the past six months. This program recognizes the needs of ... receive at least $75,000 a year, tax free, with annual ... will be eligible for annual payments of $100,000 based on ...
(Date:5/22/2015)... YORK , 22 de mayo de ... DPRX ), una compañía farmacéutica de ... comercialización de Locilex® (pexiganan cream 0.8%), y ... una presentación de póster destacando el diseño ... 3 de la Compañía que evalúan Locilex®, ...
(Date:5/22/2015)... N.C. , May 22, 2015  Effective ... to pharmaceutical brand recognition and success. ... conducted a study to provide pharmaceutical and biotech ... investment (FTEs and budget) that are being channeled ... and biotech marketing managers can utilize this report ...
Breaking Medicine Technology:Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 2Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 3Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 4Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 5Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 6Effective Marketing Services Group Critical for Pharmaceutical Brand Recognition 2
... and Chicago To Launch,Collaborative Initiative, NEW YORK, ... speed,treatment and cures for pediatric brain tumors and ... the initial phase of a tissue,bank consortium designed ... and cures for these types of cancer, where ...
... Study to Evaluate Preventive Treatment of ... Life Threatening Vulnerable Plaques, ROTTERDAM, Netherlands and DOYLESTOWN, ... Professor Patrick W. Serruys,successfully placed a vProtect(TM) Luminal Shield ... 64-year-old man at Erasmus Medical,Center in Rotterdam. This case ...
Cached Medicine Technology:Children's Brain Tumor Foundation's Tissue Bank Consortium May Solve Dire Problem in Pediatric Cancer Research 2Children's Brain Tumor Foundation's Tissue Bank Consortium May Solve Dire Problem in Pediatric Cancer Research 3Patient Receives vProtect(TM) Luminal Shield in First-Ever Vulnerable Plaque Clinical Trial 2Patient Receives vProtect(TM) Luminal Shield in First-Ever Vulnerable Plaque Clinical Trial 3
(Date:5/25/2015)... Iowa (PRWEB) May 25, 2015 ... Excellence awards for design of the wastewater ... City, Iowa.    The project received a National Recognition Award from ... Honor Award from ACEC – Iowa. Competitions held ... achievements. , The $50.2 million expansion is Iowa City’s ...
(Date:5/25/2015)... (PRWEB) May 25, 2015 ProDrop Light Show ... own VJ neon light backdrops with a click of a mouse. ... and much more all within Final Cut Pro X. , ProDrop ... such as drop zones, kaleidoscope and much more leaving infinite possibilities ... Show drop zones and text presets, users can apply their ...
(Date:5/25/2015)... (PRWEB) May 25, 2015 After the ... the radical science-based human wellness company Trivedi Master ... event from their world-class series titled, “Consciousness is Power.” ... on June 13, 2015 at the routinely allotted time ... The event will be made available to the public ...
(Date:5/25/2015)... White Plains, NY (PRWEB) May 25, 2015 ... LEED AP, principal of PBDW Architects in New York City, ... which is part of the hospital’s ongoing Legacy Lobby Lecture ... campus in White Plains. White is the great grandson of ... firm responsible for the design of Burke’s campus 100 years ...
(Date:5/24/2015)... Kong (PRWEB) May 25, 2015 Pacific Prime has ... three part report looking at the cost of individual international ... Destinations, Article 2 looks at the cost of health insurance in ... , Focusing on, Hong Kong , ... the UAE , the UK ...
Breaking Medicine News(10 mins):Health News:Stanley Consultants’ Expansion of Iowa City Wastewater Treatment Plant Wins National Award 2Health News:Stanley Consultants’ Expansion of Iowa City Wastewater Treatment Plant Wins National Award 3Health News:Developers at Pixel Film Studios Release of ProDrop Light Show for Final Cut Pro X. 2Health News:Hundreds of People Are Thrilled to Hear that Trivedi Master Wellness™ Promises to Hold Another Workshop in June 2015 2Health News:Hundreds of People Are Thrilled to Hear that Trivedi Master Wellness™ Promises to Hold Another Workshop in June 2015 3Health News:Burke Rehabilitation Hospital Welcomes Architect Samuel White, Descendant of McKim, Mead and White, for Legacy Lobby Lecture 2Health News:Burke Rehabilitation Hospital Welcomes Architect Samuel White, Descendant of McKim, Mead and White, for Legacy Lobby Lecture 3Health News:Pacific Prime Releases 2nd Article of Cost of Health Insurance Report 2
... study of sexual risk behaviors within long-term couples in ... much risk in their sexual behavior when they know ... as when they know their partner is already infected. ... antiretroviral therapy and in intensive counseling do engage in ...
... Boston University School of Medicine (BUSM) have discovered that ... have the propensity to become autoantigens. In a companion ... with dead cells and that the resulting DSautoantigen complexes ... in-vitro and in mouse models. These findings, which appear ...
... Slone Epidemiology Center, in collaboration with the Centers for ... Public Health, have reported widespread and increasing medication use ... in the American Journal of Obstetrics and Gynecology ... status, maternal age, race/ethnicity and state of residence. ...
... PA April 22, 2011 - Sanofi Pasteur, the ... NYSE: SNY), announced today that the U.S. Food and ... indication for its meningococcal conjugate vaccine, Menactra (Meningococcal [Groups ... Vaccine), to include a two-dose schedule for infants and ...
... (HealthDay News) -- While it may be true that beauty ... model helps reveal what,s behind peoples, ideas of facial attractiveness. ... "average" faces and those who fit the conventional notion of ... "femininity" in women. But psychologists Christopher P. Said of New ...
... American Society of Pediatric Otolaryngology (ASPO) will hold its ... 2011 Combined Otolaryngology Spring Meetings (COSM) - a joint ... During the ASPO meeting, hundreds of pieces of new ... will be presented focusing on children,s ear, nose, and ...
Cached Medicine News:Health News:Fighting HIV in South Africa should focus on couples, study finds 2Health News:Fighting HIV in South Africa should focus on couples, study finds 3Health News:Researchers identify novel pathophysiologic mechanism responsible for autoimmunity 2Health News:Researchers report widespread use of medications among pregnant women 2Health News:Sanofi Pasteur announces FDA approval of menactra meningococcal conjugate vaccine indication for infants 2Health News:What Makes a Face Appealing to the Opposite Sex? 2Health News:Scientific session and new research highlights from the American Society of Pediatric Otolaryngology Meeting 2
... Flowstar is a compact and digital ... The investigation starts automatically when the ... volume scales can be adjusted and ... user selectable. Siroky flow plots can ...
UroPass Open Tip Ureteral Stents perfect over-the-wire placement with a combination of flexibility and rigidity for comfort and control. When it comes to stent designs, UroPass is a proven leader....
... ACMI™ Uro-Guide Open ... the first silicone over-the-wire ... classic Double-J design with ... are composed of time-tested ...
... Open Tip Ureteral Stents combine a unique ... while remembering its shape with a chemically ... moistened. The result is a stent that ... and patient comfort. Lubri-Flex® is available in ...
Medicine Products: